T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.76B |
| 2 |
Cigna
CI
|
+$1.44B |
| 3 |
Bristol-Myers Squibb
BMY
|
+$1.26B |
| 4 |
Occidental Petroleum
OXY
|
+$763M |
| 5 |
Danaher
DHR
|
+$762M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$2.46B |
| 2 |
Wynn Resorts
WYNN
|
+$1.11B |
| 3 |
Netflix
NFLX
|
+$1.03B |
| 4 |
PCP
PRECISION CASTPARTS CORP
PCP
|
+$975M |
| 5 |
TWTR
Twitter, Inc.
TWTR
|
+$909M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.87% |
| 2 | Financials | 13.64% |
| 3 | Consumer Discretionary | 13.54% |
| 4 | Industrials | 10.67% |
| 5 | Technology | 10.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DF
1101
DELISTED
Dean Foods Company
DF
| $21.8M | ﹤0.01% |
1,350,678
+1,070
| +0.1% | +$18.7K |
|
1102
Agnico Eagle Mines
AEM
$91.3B
| $21.8M | ﹤0.01% |
765,790
-308,960
| -29% | -$9.59M |
|
1103
FIVE9
FIVN
$2.53B
| $21.7M | ﹤0.01% |
4,145,430
+62,800
| +2% | +$345K |
|
1104
Robert Half
RHI
$4.48B
| $21.7M | ﹤0.01% |
390,553
+13,500
| +4% | +$772K |
|
1105
Piper Sandler
PIPR
$5.54B
| $21.6M | ﹤0.01% |
1,982,240
-1,240,340
| -38% | -$15.5M |
|
|
CSLT
1106
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $21.6M | ﹤0.01% |
2,648,423
| – | – |
|
1107
Church & Dwight Co
CHD
$24B
| $21.5M | ﹤0.01% |
530,426
+5,700
| +1% | +$239K |
|
|
CAMP
1108
DELISTED
CalAmp Corp.
CAMP
| $21.5M | ﹤0.01% |
51,204
-44
| -0.1% | -$19.2K |
|
|
AZPN
1109
DELISTED
ASPEN TECHNOLOGY INC
AZPN
| $21.5M | ﹤0.01% |
471,491
+12,200
| +3% | +$556K |
|
1110
F5
FFIV
$23.6B
| $21.4M | ﹤0.01% |
177,905
-390
| -0.2% | -$48K |
|
|
PPS
1111
DELISTED
Post Properties
PPS
| $21.4M | ﹤0.01% |
393,088
-17,700
| -4% | -$996K |
|
|
ATYR
1112
aTyr Pharma
ATYR
$54.2M
| $21.4M | ﹤0.01% |
+85,003
| New | +$26.4M |
|
|
IPG
1113
DELISTED
Interpublic Group of Companies
IPG
| $21.3M | ﹤0.01% |
1,107,419
+24,900
| +2% | +$517K |
|
|
AKRX
1114
DELISTED
Akorn Inc
AKRX
| $21.3M | ﹤0.01% |
487,872
+53,023
| +12% | +$2.45M |
|
1115
Clean Harbors
CLH
$16.9B
| $21.2M | ﹤0.01% |
395,260
+55,330
| +16% | +$3.09M |
|
1116
Mohawk Industries
MHK
$9.42B
| $21.2M | ﹤0.01% |
111,181
+9,000
| +9% | +$1.66M |
|
1117
Eastman Chemical
EMN
$8.43B
| $21.2M | ﹤0.01% |
259,346
+1,532
| +0.6% | +$118K |
|
1118
Exponent
EXPO
$3.24B
| $21M | ﹤0.01% |
939,236
+494,420
| +111% | +$10.9M |
|
|
CTXS
1119
DELISTED
Citrix Systems Inc
CTXS
| $20.9M | ﹤0.01% |
374,044
+7,912
| +2% | +$420K |
|
|
LDR
1120
DELISTED
Landauer Inc
LDR
| $20.9M | ﹤0.01% |
585,670
+1,100
| +0.2% | +$37.5K |
|
1121
Alamo Group
ALG
$1.99B
| $20.7M | ﹤0.01% |
379,494
+57,684
| +18% | +$3.31M |
|
1122
Sally Beauty Holdings
SBH
$1.55B
| $20.6M | ﹤0.01% |
651,300
-3,400
| -0.5% | -$108K |
|
1123
Prestige Consumer Healthcare
PBH
$2.43B
| $20.4M | ﹤0.01% |
442,000
+27,600
| +7% | +$1.21M |
|
1124
PTC
PTC
$16.7B
| $20.4M | ﹤0.01% |
497,682
+23,228
| +5% | +$918K |
|
|
SIOX
1125
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $20.4M | ﹤0.01% |
+125,000
| New | +$21.2M |
|
Similar funds
T. Rowe Price Associates's Q2 2015 Portfolio in Review
As of Q2 2015, T. Rowe Price Associates held 2,615 positions worth $486B, up 0.44% from $484B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
T. Rowe Price Associates's Q2 2015 filing shows 76 new, 1,051 increased, 777 reduced and 79 closed positions. Its largest new stake was Allergan plc: 548,825 shares worth $570M. The largest sale was PHARMACYCLICS INC, an estimated $2.46B.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 21% a quarter earlier, followed by Financials and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2015 buy was Allergan plc: 548,825 shares worth $570M.
- T. Rowe Price Associates added most to Microsoft in Q2 2015, an estimated $3.76B increase.
- T. Rowe Price Associates's biggest Q2 2015 reduction was Wynn Resorts, cutting an estimated $1.11B.
- T. Rowe Price Associates fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $2.46B.
- T. Rowe Price Associates's ten largest holdings make up 14% of its $486B portfolio in Q2 2015.
- T. Rowe Price Associates opened 76 new positions and closed 79 in Q2 2015.
- T. Rowe Price Associates's portfolio value rose 0.44% quarter-over-quarter to $486B.
Based on T. Rowe Price Associates's 13F filing for Q2 2015, filed 14 Aug 2015.